Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research

Drug Testing and Analysis

Volumn 3, Issue 11-12, 2011, Pages 756-770

  Beuck, Simon ^a   Bornatsch, Wolfgang ^b   Lagojda, Andreas ^b   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b BAYER CROPSCIENCE AG   (Germany)

Author keywords

HIF stabilizers; In vitro metabolism; LC MS MS; Neutral loss scan; Preventive doping research

Indexed keywords

ACETIC ACID; ASSAYS; BIOMOLECULES; CHEMICAL DETECTION; DIRECT INJECTION; GLUCOSE; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH;

HYPOXIA-INDUCIBLE FACTOR STABILIZER; HYPOXIA-INDUCIBLE FACTORS; IN VITRO METABOLISM; IN-VITRO; ISOQUINOLINES; LC-MS-MS; LC.MS/MS; NEUTRAL LOSS SCANS; PREVENTIVE DOPING RESEARCH; STABILISER;

METABOLISM;

1 CHLORO 4 HYDROXY 6 ISOPROPOXY ISOQUINOLINE 3 CARBONYL N (2 HYDROXYETHYL)AMIDE; DRUG METABOLITE; HYPOXIA INDUCIBLE FACTOR STABILIZER; N [(1 CHLORO 4 HYDROXY 7 ISOPROPOXY ISOQUINOLIN 3 CARBONYL)AMINO]ACETIC ACID; N [(1 CHLORO 4 HYDROXY ISOQUINOLIN 3 CARBONYL)AMINO]ACETIC ACID; PERFORMANCE ENHANCING SUBSTANCE; UNCLASSIFIED DRUG;

ARTICLE; DEALKYLATION; DEHYDROGENATION; DOPING; DRUG CONJUGATION; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG RESEARCH; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 84855248903     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.365     Document Type: Article

References (26)

1. T. Tanaka, M. Nangaku Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. J. Pharmacol. Sci. 2009, 109, 24.
2. K. Bruegge, W. Jelkmann, E. Metzen Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr. Med. Chem. 2007, 14, 1853.
3. P. Urquilla Upregulation of endogenous EPO in healthy subjects by inhibition of HIF-PH. J. Am. Soc. Nephrol. 2004, 15, 546A.
4. A. Besarab, H. N. Hulter, S. Klaus, T. T. Lee, D. E. Lilienfeld, T. Neff, B. A. Piper, A. Provenzano, P. K. Yu FG-4592, A novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients. J. Am. Soc. Nephrol. 2010, 21, 95A.
5. R. K. Bruick, S. L. McKnight A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294, 1337.
6. WADA (World Anti-Doping Agency). The 2011 Prohibited List. Available at: [18 August 2011].
7. L. Yan, V. J. Colandrea, J. J. Hale Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin. Ther. Pat. 2010, 20, 1219.
8. Fibrogen Inc. FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF Prolyl Hydroxylase Inhibitor, for Treatment of Anemia in Chronic Kidney Disease. Available at: [5 May 2011].
9. Fibrogen Inc. FibroGen Licenses Oral HIF-PH Inhibitors, Including FG-2216 and FG-4592, to Astellas for the Treatment of Anemia in Europe and Other Regions. Available at: [31 May 2011].
10. S. Philipp, J. S. Jürgensen, J. Fielitz, W. M. Bernhardt, A. Weidemann, A. Schiche, B. Pilz, R. Dietz, V. Regitz-Zagrosek, K. U. Eckardt, R. Willenbrock Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur. J. Heart Fail. 2006, 8, 347.
11. Fibrogen. Novel nitrogen-containing heteroaryl compounds and methods of use thereof. US Patent No. 20040254215A1, 2004.
12. Fibrogen Inc. Treatment method for anemia. US Patent No. 20060276477A1, 2006.
13. M. Thevis, M. Kohler, N. Schlörer, W. Schänzer Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation. J. Am. Soc. Mass Spectrom. 2008, 19, 151.
14. S. Beuck, T. Schwabe, S. Grimme, N. Schlörer, M. Kamber, W. Schänzer, M. Thevis Unusual mass spectrometric dissociation pathway of protonated isoquinoline-3-carboxamides due to multiple reversible water adduct formation in the gas phase. J. Am. Soc. Mass Spectrom. 2009, 20, 2034.
15. S. Guddat, E. Solymos, A. Orlovius, A. Thomas, G. Sigmund, H. Geyer, M. Thevis, W. Schänzer High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography / tandem mass spectrometry multi-target approach. Drug Test. Analysis 2011, 3, this issue.
16. S. Beuck, I. Möller, A. Thomas, A. Klose, N. Schlörer, W. Schänzer, M. Thevis Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Anal. Bioanal. Chem. 2011, DOI:10.1007/s00216-011-4931-5
17. T. Kuuranne, A. Leinonen, W. Schänzer, M. Kamber, R. Kostiainen, M. Thevis Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metab. Dispos. 2008, 36, 571.
18. M. Thevis, I. Möller, A. Thomas, S. Beuck, G. Rodchenkov, W. Bornatsch, H. Geyer, W. Schänzer Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal. Bioanal. Chem. 2010, 396, 2479.
19. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019.
20. W. M. Bernhardt, M. S. Wiesener, P. Scigalla, J. Chou, R. E. Schmieder, V. Günzler, K. U. Eckardt Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 2010, 21, 2151.
21. M. Thevis, H. Geyer, U. Mareck, W. Schänzer Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. 2005, 40, 955.
22. R. Provenzano, G. Fadda, M. Bernardo, C. James, G. Kochendoerfer, T. Lee, T. Neff, R. H. Ellison, B. A. Piper FG-2216, A novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD. Am. J. Kidney Dis. 2008, 51, B80.
23. M. Thevis, H. Geyer, M. Kamber, W. Schänzer Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test. Analysis 2009, 1, 387.
24. P. Benkimoun Police find unlicensed drugs after trawling bins. BMJ 2009, 339, b4201.
25. H. F. Bunn New agents that stimulate erythropoiesis. Blood 2007, 109, 868.
26. E. P. Cummins, E. Berra, K. M. Comerford, A. Ginouves, K. T. Fitzgerald, F. Seeballuck, C. Godson, J. E. Nielsen, P. Moynagh, J. Pouyssegur, C. T. Taylor Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. P. Natl. Acad. Sci. USA 2006, 103, 18154.